Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.51 |
| ▸ | NTRK1 | P04629 | 6/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 7/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 2/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL612289 | 0.87 | GPR119 (0.43) | GPR119NTRK1HDAC6RETHDAC4 | |
| SCHEMBL10058408 | 0.87 | GPR119 (0.48) | GPR119 | |
| SCHEMBL612683 | 0.84 | GPR119 (0.36) | GPR119NTRK1 | |
| SCHEMBL612552 | 0.82 | GPR119 (0.37) | GPR119NTRK1 | |
| SCHEMBL10058394 | 0.82 | GPR119 (0.40) | GPR119NTRK1HDAC6RETSYK | |
| SCHEMBL610104 | 0.81 | GPR119 (0.46) | GPR119 | |
| SCHEMBL609801 | 0.81 | GPR119 (0.36) | GPR119NTRK1 | |
| SCHEMBL609800 | 0.81 | GPR119 (0.36) | GPR119NTRK1 | |
| SCHEMBL10058406 | 0.80 | GPR119 (0.47) | GPR119HDAC6HDAC8HDAC1 | |
| SCHEMBL10058415 | 0.79 | GPR119 (0.47) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040953-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040953-A1 | Compounds for the Treatment of Metabolic Disorders | GPR119, GPR132, FFAR2 | GPR119 1/4885NTRK1 3765/4885HDAC6 2312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.